Waivers, Exceptions and Why the Answer Is No

Part of Principal Investigator (PI) Training: Eligibility and the Enrollment Decision.

About 4 minutes. Free, in your language, no account needed.

Why this matters

A patient in front of you wants the trial. They miss one criterion. They are otherwise perfect, the sponsor wants recruitment, and everyone involved can construct a reason why this particular criterion does not really matter for this particular person.

This is the single most reliable way for a well-intentioned investigator to end up in serious difficulty. It is worth knowing exactly why the answer is no, so that you can give it quickly and without agonizing.

What the guideline says

Three sections of Annex 1, read together, are direct. Section 2.5.2: the investigator should comply with the protocol. Section 2.5.4: the investigator should follow the protocol and deviate only where necessary to eliminate an immediate hazard to trial participants. Section 2.5.3: every deviation is documented and reviewed, and for the important ones the investigator explains the deviation and puts measures in place to prevent it happening again.

Read that carefully. Prospective approval to depart from the protocol for a specific person is not one of the mechanisms it describes. There are exactly two legitimate routes when a protocol requirement will not work:

1. Amend the protocol — with sponsor agreement and IRB/IEC approval, so the rule changes for everyone.
2. Do not enroll this person.

There is a third route reserved for one situation only, covered below, and it is not about eligibility.

Why the "eligibility waiver" fell out of favor

For years it was common for sponsors to grant written exceptions allowing a named participant to enroll despite a criterion they did not meet. Regulators across regions have criticized the practice, and the reasoning is worth understanding rather than memorizing.

• It is a protocol change without the review that protects participants. The criterion exists because a protocol author judged the risk. A per-participant exception overrides that judgment without the ethics review that a genuine change requires.
• It corrodes the criteria. One exception is a judgment call. Twenty exceptions are an unapproved protocol, and the trial no longer studies the population it says it studies.
• It puts the exposure on the participant and the benefit elsewhere. The participant carries the additional risk. The sponsor gets the enrollment. That asymmetry is exactly what ethics review exists to prevent.
• It usually signals a design problem. If the same criterion blocks candidate after candidate, the criterion is wrong for the real-world population. That is an amendment conversation, and it helps every site rather than one patient.

Some sponsors still ask. You are entitled to decline, and declining is the position that survives inspection.

The one real exception

Section 2.5.4 permits the investigator to deviate from the protocol to eliminate an immediate hazard to trial participants, without prior agreement or approval. Section 2.5.5 then requires prompt notification — the deviation, its reasons and any proposed amendment communicated to the sponsor and, as required, the IRB/IEC and regulatory authorities.

The scope of that exception is narrower than it first appears, and two boundaries matter:

• It is about removing a danger, not about creating an opportunity. Stopping a dose because a participant is deteriorating is inside it. Enrolling someone who does not qualify is not.
• It applies to a hazard that is immediate. Something that can wait for a sponsor telephone call should wait for one.

An eligibility departure is never an immediate-hazard deviation, because not enrolling somebody harms nobody.

How to say no well

The clinical difficulty is not the rule. It is the conversation with a patient who wants access to something they hope will help.

Three things make it easier. Say no to the trial, not to the patient: your next sentence should be about what you can offer — standard care, another study, a re-screen if the protocol permits it, referral elsewhere. Explain the criterion as protection rather than bureaucracy, because that is what it is. And where a criterion is repeatedly blocking suitable people, take that to the sponsor as feasibility data — that is how criteria actually get changed, and it helps every site in the study.

Key takeaways

• §2.5.2 and §2.5.4 leave no room for a planned per-participant departure. The routes are amendment or non-enrollment.
• Eligibility waivers have been widely criticized because they bypass ethics review, corrode the criteria, and shift risk onto the participant.
• §2.5.4's exception is for eliminating an immediate hazard — never for enrolling someone who does not qualify — and §2.5.5 requires prompt notification.
• Decline the trial, not the patient, and feed recurring blocks back to the sponsor as amendment evidence.